Figure 3.

CHM1³¹⁹/HLA-A*02:01-specific TCR-transgenic CD8⁺ T cells (CHM1 T cells) and XVir-N-31 synergistically lyse tumor cells in vitro. (A) Contact-dependent tumor growth of A673 was studied in xCELLigence assays to determine tumor cell detachment (i.e. killing) after XVir-N-31 at indicated MOI and n.-sp CD8 T cells (E:T = 1:1) and combinations of both, with respective controls. Infection with XVir-N-31 and addition of T cells is indicated with symbols. (B) Data complexity from (A) was reduced for better comprehensibility to experimental conditions only containing T cells. (C) T cell-mediated tumor cell killing was analyzed 12h and 24h after addition of T cells by subtracting respective cell index values of e.g. mock from n.-sp. T cells. (D–F) CHM1 CD8 T cell killing of A673 tumor cells was evaluated at indicated MOI, as described for n.-sp. CD8 T cells. (G, H) The probability of synergistic interactions using XVir-N-31 and CHM1 CD8 T cells with regard to tumor killing was assessed by SRB assays at 24h after addition of T cells (i.e. 48hpi) together with the SynergyFinder tool in R (experiments were performed in biological replicates and repeated, n=2). Synergy score explanation: interactions larger than 10 are considered as likely synergistic; interactions from -10 to 10 are most likely additive and interactions less than -10 are likely to be antagonistic. Significance levels are indicated as asterisks: * p < 0.05, ** p < 0.01, p*** < 0.005; Tukey’s multiple comparison within ordinary ANOVA was performed in (C) and (F) using Prism 9. Error bars indicate the SEM.